Nephrology · USMLE Step 1 and Step 2

Diabetic Nephropathy song

Diabetic Nephropathy - Pathophysiology & Management, as a song. Hear the short teaser here. The full song is on YouTube and Spotify.

Diabetic Nephropathy

Full song on YouTube ↗Spotify ↗

Key points in this song10

Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in the United States, occurring in both Type 1 and Type 2 diabetes mellitus.
The earliest detectable sign is microalbuminuria (30–300 mg/day), which precedes overt proteinuria and indicates glomerular basement membrane damage.
Hyperfiltration and increased GFR occur early in disease due to afferent arteriolar dilation and efferent arteriolar constriction driven by hyperglycemia.
The classic histologic finding is Kimmelstiel-Wilson nodules (nodular glomerulosclerosis), representing mesangial matrix expansion with PAS-positive deposits.
ACE inhibitors or ARBs are first-line renoprotective agents regardless of blood pressure, reducing intraglomerular pressure by dilating the efferent arteriole.
Diffuse glomerulosclerosis is more common than nodular sclerosis and is the earliest histologic change seen in diabetic nephropathy.
SGLT-2 inhibitors (e.g., empagliflozin, canagliflozin) have demonstrated independent renoprotective and cardiovascular benefits in diabetic nephropathy beyond glycemic control.
Blood pressure target in diabetic nephropathy is less than 130/80 mmHg to slow progression of proteinuria and GFR decline.
Dual blockade with both ACE inhibitors and ARBs is contraindicated due to increased risk of hyperkalemia and acute kidney injury without additional renal benefit.
Progression follows a predictable sequence: hyperfiltration → microalbuminuria → macroalbuminuria → declining GFR → ESRD, typically over 10–20 years.